vai alle Pubblicazioni
Publications prior to 2004
1. Rimondini R
, Sommer W, Heilig M. “A temporal threshold for induction of
persistent alcohol preference: behavioural evidence in a rat model
of intermittent intoxication.” J STUD ALCOHOL. 2003 Jul;
64(4):445-9.
2. Hansson AC, Sommer W,
Rimondini R, Andbjer B, Stromberg I, Fuxe K. “c-fos
reduces corticosterone-mediated effects on neurotrophic factor
expression in the rat hippocampal CA1 region.” J NEUROSCI. 2003 Jul
9; 23(14):6013-22.
3. Kela J, Salmi P,
Rimondini R, Heilig M, Wahlestedt C. “Behavioural
analysis of melanin-concentrating hormone in rats: evidence for
orexigenic and anxiolytic properties.” REGUL PEPT. 2003 Jul
15;114(2-3):109-14.
4. Rimondini R
, Agren G, Borjesson S, Sommer W, Heilig M. “Persistent behavioral
and autonomic supersensitivity to stress following prenatal stress
exposure in rats.” BEHAV BRAIN RES. 2003 Mar 18;
140(1-2):75-80.
5. Thorsell A,
Rimondini R, Heilig M. “Blockade of central
neuropeptide Y (NPY) Y2 receptors reduces ethanol
self-administration in rats.” NEUROSCI LETT 2002 Oct 25;
332(1):1-4.
6. Rimondini R
, Sommer W, Heilig M. “Effects of tiagabine and diazepam on operant
ethanol self-administration in the rat.” J STUD ALCOHOL. 2002 Jan;
63(1):100-6.
7. Moller C, Sommer W,
Thorsell A, Rimondini R, Heilig M. “Anxiogenic-like
action of centrally administered glucagon-like peptide-1 in a
punished drinking test.” PROG NEUROPSYCHOPHARMACOL BIOL PSYCHIATRY
2002 Jan; 26(1):119-22.
8. Thorsell A, Caberlotto L,
Rimondini R, Heilig M. “Leptin suppression of
hypothalamic NPY expression and feeding, but not amygdale NPY
expression and experimental anxiety.” PHARMACOL BIOCHEM BEHAV. 2002
Mar;71(3):425-30.
9. Rimondini R
, Arlinde C, Sommer W, Heilig M. “Long-lasting increase in
voluntary ethanol consumption and transcriptional regulation in the
rat brain after intermittent exposure to alcohol.” FASEB J. 2002
Jan; 16(1):27-35.
10. Caberlotto L, Thorsell A, Rimondini
R, Sommer W, Hyytia P, Heilig M. “Differential expression
of NPY and its receptors in alcohol-preferring AA and
alcohol-avoiding ANA rats.” ALCHOL CLIN EXP RES. 2001 Nov;
25(11):1564-9.
11. Ferre S, Popoli P, Gimenez-Llort L,
Rimondini R, Muller CE, Stromberg I, Ogren SO, Fuxe
K. “Adenosine/dopamine interaction: implications for the treatment
of Parkinson's disease.” PARKINSONISM RELAT DISORD. 2001 Jul;
7(3):235-241.
12. Sommer W, Moller C, Wiklund L, Thorsell A,
Rimondini R, Nissbrandt H, Heilig M. “Local
5,7-dihydroxytryptamine lesions of rat amygdala: release of
punished drinking, unaffected plus-maze behavior and ethanol
consumption.” NEUROPSYCHOPHARMACOLOGY 2001 Apr; 24 (4):430-40.
13. Thorsell A, Michalkiewicz M, Dumont Y,
Quirion R, Caberlotto L, Rimondini R, Mathe AA,
Heilig M. “Behavioral insensitivity to restraint stress, absent
fear suppression of behaviour and impaired spatial learning
in transgenic rats with hippocampal neuropeptide Y overexpression.”
Proc Natl Acad Sci U S A. 2000 Nov 7; 97(23):12852-7.
14. Ferre S, Rimondini R, Popoli
P, Reggio R, Pezzola A, Hansson AC, Andersson A, Fuxe K.
“Stimulation of adenosine A1 receptors attenuates dopamine D1
receptor-mediated increase of NGFI-A, c-fos and jun-B mRNA levels
in the dopamine-denervated striatum and dopamine D1
receptor-mediated turning behaviour.” EUR J NEUROSCI. 1999
Nov;11(11):3884-92.
15. Rimondini R , Fuxe K, Ferre
S. “Multiple intramembrane receptor-receptor interactions in the
regulation of striatal dopamine D2 receptors.” NEUROREPORT 1999 Jul
13;10(10):2051-4.
16. Ferre S, Popoli P, Rimondini
R, Reggio R, Kehr J, Fuxe K. “Adenosine A2A and group I
metabotropic glutamate receptors synergistically modulate the
binding characteristics of dopamine D2 receptors in the rat
striatum.” NEUROPHARMACOLOGY 1999 Jan; 38(1):129-40.
17. Misane I, Klusa V, Dambrova M, Germane S,
Duburs G, Bisenieks E, Rimondini R, Ogren SO.
"Atypical" neuromodulatory profile of glutapyrone, a representative
of a novel'class' of amino acid-containing dipeptide-mimicking
1,4-dihydropyridine (DHP) compounds: in vitro and in vivo studies.”
EUR NEUROPSYCHOPHARMACOL. 1998 Dec; 8(4):329-47.
18. Rimondini R , Ferre S,
Gimenez-Llort L, Ogren SO, Fuxe K. “Differential effects of
selective adenosine A1 and A2A receptor agonists on dopamine
receptor agonist-induced behavioural responses in rats.” EUR J
PHARMACOL 1998 Apr 24; 347(2-3):153-8.
19. Popoli P, Betto P, Rimondini
R, Reggio R, Pezzola A, Ricciarello G, Fuxe K, Ferre S.
“Age-related alteration of the adenosine/dopamine balance in the
rat striatum.” BRAIN RES. 1998 Jun 8; 795(1-2):297-300.
20. Dall'Olio R, Rimondini R,
Gandolfi O. “Effects of competitive and non-competitive NMDA
receptor antagonists on behavioral responses induced by 7-OH DPAT
and quinpirole in rats.” PHARMACOL RES. 1997 Sep; 36(3):203-9.
21. Picciotto MR, Zoli M, Rimondini
R, Lena C, Marubio LM, Pich EM, Fuxe K, Changeux JP.
“Acetylcholine receptors containing the beta2 subunit are involved
in the reinforcing properties of nicotine.” NATURE 1998 Jan 8;
391(6663):173-7.
22. Rimondini R , Ferre S, Ogren
SO, Fuxe K. “Adenosine A2A agonists: a potential new type of
atypical antipsychotic.” NEUROPSYCHOPHARMACOLOGY 1997 Aug;
17(2):82-91.
23. Fuxe K, Bjelke B, Andbjer B, Grahn H,
Rimondini R, Agnati LF. “Endothelin-1 induced lesions
of the frontoparietal cortex of the rat. A possible model of focal
cortical ischemia.” NEUROREPORT 1997 Jul 28; 8(11):2623-9.
24. Sommer W, Rimondini R,
O'Connor W, Hansson AC, Ungerstedt U, Fuxe K. “Intrastriatally
injected c-fos antisense oligonucleotide interferes with
striatonigral but not striatopallidal gamma-aminobutyric acid
transmission in the conscious rat.” PROC NATL ACAD SCI U S A. 1996
Nov 26; 93(24):14134-9.
25. Ferraro L, O'Connor WT, Li XM,
Rimondini R, Beani L, Ungerstedt U, Fuxe K,
Tanganelli S. “Evidence for a differential cholecystokinin-B and -A
receptor regulation of GABA release in the rat nucleus accumbens
mediated via dopaminergic and cholinergic mechanisms.” NEUROSCIENCE
1996 Aug; 73(4):941-50.
26. Rimondini R , O'Connor WT,
Sillard R, Mutt V, Ungerstedt U, Fuxe K. “The secretory trypsin
inhibitor like-peptide, PEC-60 increases dopamine D2 receptor
agonist induced inhibition of GABA release in the dorsolateral
neostriatum of the awake freely moving rat. An in vivo
microdialysis study.” REGUL PEPT. 1996 Feb 22; 61(2):111-7.
27. Dall'Olio R, Rimondini R,
Gandolfi O. “Effect of NMDA receptor antagonists on D1, D2 and
D1/D2 mediated behaviors in intact rats.” PSYCHOPHARMACOLOGY (Berl)
1996 Jan; 123(2):187-90.
28. Dall'Olio R, Rimondini R,
Gandolfi O. “The competitive NMDA antagonists CGP 43487 and APV
potentiate dopaminergic function.” PSYCHOPHARMACOLOGY (Berl) 1995
Apr; 118(3):310-5.
29. Rimondini R , O'Connor WT,
Ferre S, Sillard R, Agerberth B, Mutt V, Ungerstedt U, Fuxe K.
“PEC-60 increases dopamine but not GABA release in the dorsolateral
neostriatum of the halothane anaesthetized rat. An in vivo
microdialysis study.” NEUROSCI LETT. 1994 Aug 15;
177(1-2):53-7.
30. Gandolfi O, Rimondini R,
Dall'Olio R. “D-cycloserine decreases both D1 and D2 dopamine
receptors number and their function in rat brain.” PHARMACOL
BIOCHEM BEHAV. 1994 Jun; 48(2):351-6.
31. Gandolfi O, Dall'Olio R, Rimondini
R, Bongrani S, Valsecchi B. “Repeated administrations of
(-)-deprenyl increase [3H]MK801 binding in rat brain and antagonize
the impairment of passive avoidance conditioning induced by
-methyl-D-aspartate receptor antagonists.” NEUROSCI LETT. 1994 Jan
3;165(1-2):113-6.
32. Dall'Olio R, Rimondini R,
Gandolfi O. “The NMDA positive modulator D-cycloserine inhibits
dopamine-mediated behaviors in the rat.” NEUROPHARMACOLOGY 1994
Jan; 33(1):55-9.
33. Gandolfi O, Rimondini R,
Dall'Olio R. “The modulation of dopaminergic transmission in the
striatum by MK-801 is independent of presynaptic mechanisms.”
NEUROPHARMACOLOGY 1992 Nov; 31(11):1111-4.
Review
1. Fuxe K, Stromberg I,
Popoli P, Rimondini R, Torvinen M, Ogren SO, Franco
R, Agnati LF, Ferre S. “Adenosine receptors and Parkinson's
disease. Relevance of antagonistic adenosine and dopamine receptor
interactions in the striatum.” ADV NEUROL. 2001;86:345-53.
Review.